|
|
(14 intermediate revisions not shown) |
Line 11: |
Line 11: |
| | | |
| <title>Safie by Technion-Israel</title> | | <title>Safie by Technion-Israel</title> |
- | <meta http-equiv="content-type" content="text/html; charset=utf-8" /> | + | <meta http-equiv="content-type" content="textwhy/html; charset=utf-8" /> |
| <meta name="description" content="" /> | | <meta name="description" content="" /> |
| <meta name="keywords" content="" /> | | <meta name="keywords" content="" /> |
Line 172: |
Line 172: |
| <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#azo">Azobenzene</a></li> | | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#azo">Azobenzene</a></li> |
| <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#hk">Histidine Kinase</a></li> | | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#hk">Histidine Kinase</a></li> |
- | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#newmethod">New Method</a></li> | + | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#newmethod">New Standard</a></li> |
| <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#protocol">Protocols</a></li> | | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#protocol">Protocols</a></li> |
| <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#notebook">Lab Notebook</a></li> | | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Project#notebook">Lab Notebook</a></li> |
Line 180: |
Line 180: |
| <li id="parent"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling">Modeling</a> | | <li id="parent"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling">Modeling</a> |
| <ul class="sub1"> | | <ul class="sub1"> |
- | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#whyworks">Why should it work</a></li> | + | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#whyworks">Why it should work</a></li> |
- | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#whyfail">Why should it fail</a></li> | + | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#whyfail">Why it should fail</a></li> |
| <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#splint">RNA Splint</a></li> | | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#splint">RNA Splint</a></li> |
| <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#biofilm">Synthetic Biofilm<br>Formation</a></li> | | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Modeling#biofilm">Synthetic Biofilm<br>Formation</a></li> |
Line 232: |
Line 232: |
| <ul class="sub1"> | | <ul class="sub1"> |
| <li id="child1"><a href="https://igem.org/2014_Judging_Form?id=1343" target="_blank">Judging Form</a></li> | | <li id="child1"><a href="https://igem.org/2014_Judging_Form?id=1343" target="_blank">Judging Form</a></li> |
- | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Judging#results">Results</a></li>
| |
| <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Judging#biobrick">BioBricks</a></li> | | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Judging#biobrick">BioBricks</a></li> |
- | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Judging#criteria">Judging Criteria</a></li> | + | <li id="child1"><a href="https://2014.igem.org/Team:Technion-Israel/Judging#results">Results</a></li> |
| </ul> | | </ul> |
| </li> | | </li> |
Line 328: |
Line 327: |
| <center><h2 style="box-shadow:0px 0px 1px 1px rgba(0,0,0,0.25); border-radius:0.35em; font-weight:700; padding:1em; font-size:2em;">Beta System</h2> | | <center><h2 style="box-shadow:0px 0px 1px 1px rgba(0,0,0,0.25); border-radius:0.35em; font-weight:700; padding:1em; font-size:2em;">Beta System</h2> |
| <p style="line-height:1.75em;"> | | <p style="line-height:1.75em;"> |
- | According to the model <a href="https://2014.igem.org/Team:Technion-Israel/Modeling#whyfail">"Why Should it Fail"</a> of the Alpha System, we can see that it has some problems. We decided to test new methods to reduce the noise in our system. One idea was a new design – the Beta System, inspired by the noise reduction mechanism described by Goni-Moreno and Amos. (Goni-Moreno & Amos, 2012). | + | <img src="https://static.igem.org/mediawiki/2014/0/00/Technion-Israel-Beta_System.png" width="1100px"><br> |
| + | According to the model <a href="https://2014.igem.org/Team:Technion-Israel/Modeling#whyfail">"Why it Should Fail"</a> of the Alpha System, we can see that it has some problems. We decided to test new methods to reduce the noise in our system. One idea was a new design – the Beta System, inspired by the noise reduction mechanism described by Goni-Moreno and Amos. (Goni-Moreno & Amos, 2012). |
| We used a double repression Toggle Switch similar to that described by Gardner et al. (Gardner, Cantor, & Collins, 2000)), to filter the inputs of our system. This makes the cell-to-cell communication more accurate, while affording them an internal memory capacity.<br> | | We used a double repression Toggle Switch similar to that described by Gardner et al. (Gardner, Cantor, & Collins, 2000)), to filter the inputs of our system. This makes the cell-to-cell communication more accurate, while affording them an internal memory capacity.<br> |
| This system consists of three main circuits:<br> | | This system consists of three main circuits:<br> |
Line 363: |
Line 363: |
| <b>(2)</b> A genetic gate which can produce large amounts of AHL (an "antenna").<br> | | <b>(2)</b> A genetic gate which can produce large amounts of AHL (an "antenna").<br> |
| <img src="https://static.igem.org/mediawiki/2014/7/74/Technion-Israel-betaSC.png"> | | <img src="https://static.igem.org/mediawiki/2014/7/74/Technion-Israel-betaSC.png"> |
- | <b>This circuit contains two parts:</b><br> | + | <b><br><br>This circuit contains two parts:</b><br> |
| The first part consists of the promoter Pcat, a constitutive promoter, which regulates LuxR expression in excess at all times. The LuxR protein can bind to AHL produced by neighboring cells, activating the Computational Circuit.<br> | | The first part consists of the promoter Pcat, a constitutive promoter, which regulates LuxR expression in excess at all times. The LuxR protein can bind to AHL produced by neighboring cells, activating the Computational Circuit.<br> |
| The second part consists of the promoter, PT7 RNA polymerase, which is controlled by the T7 polymerase synthesized by the Toggle Switch, and regulates the expression of LuxI – an enzyme that produces AHL. When the PT7 promoter is activated, it produces large amounts of AHL. This amplifies the signal produced by the toggle switch, before it is diffuses out through the lossy channel.<br> | | The second part consists of the promoter, PT7 RNA polymerase, which is controlled by the T7 polymerase synthesized by the Toggle Switch, and regulates the expression of LuxI – an enzyme that produces AHL. When the PT7 promoter is activated, it produces large amounts of AHL. This amplifies the signal produced by the toggle switch, before it is diffuses out through the lossy channel.<br> |
Line 388: |
Line 388: |
| To screen for the positive colony with the positive RNA splint and the functionality of LuxI, the detector strain assay will be done (the same screening method from gate 1)<br></p> | | To screen for the positive colony with the positive RNA splint and the functionality of LuxI, the detector strain assay will be done (the same screening method from gate 1)<br></p> |
| | | |
- | <h1>LuxI-Inspiration</h1> | + | <h1><br><br>LuxI-Inspiration</h1> |
| <p><b>RNA splint:</b> bridges between A protein RNA and B protein RNA. The splint enables the ligation of two RNA molecules. In order for the ligation of the 2 RNA molecules to occur a T4 RNA ligase is needed. T4 RNA Ligase is the enzyme from the phage that makes this ligation between two RNA molecules, it recognizes a specific site (this will be addressed later on). This is the preferable method.<br> | | <p><b>RNA splint:</b> bridges between A protein RNA and B protein RNA. The splint enables the ligation of two RNA molecules. In order for the ligation of the 2 RNA molecules to occur a T4 RNA ligase is needed. T4 RNA Ligase is the enzyme from the phage that makes this ligation between two RNA molecules, it recognizes a specific site (this will be addressed later on). This is the preferable method.<br> |
- | <b>The design using luxI:</b> | + | <b>The design using luxI:</b><br><br> |
| <img src="https://static.igem.org/mediawiki/2014/4/4b/Technion-Israel-RNALuxI.png"><br></p> | | <img src="https://static.igem.org/mediawiki/2014/4/4b/Technion-Israel-RNALuxI.png"><br></p> |
- | <h1>CM Resistance</h1> | + | <h1><br><br>CM Resistance</h1> |
| <p>RNA splint is an in-vitro method described for the ligation of 2 RNA molecules. (M.R. Stark, J.A. Pleiss, (2006)<br> | | <p>RNA splint is an in-vitro method described for the ligation of 2 RNA molecules. (M.R. Stark, J.A. Pleiss, (2006)<br> |
- | For a simple and robust screen CM split is preferred over the split of luxI<br> | + | For a simple and robust screen CM split is preferred over the split of luxI<br><br><br> |
| <img src="https://static.igem.org/mediawiki/2014/b/be/Technion-Israel-RNAwhole.png"></p> | | <img src="https://static.igem.org/mediawiki/2014/b/be/Technion-Israel-RNAwhole.png"></p> |
- | <h1>Some background about the components needed for the described system</h1> | + | <h1><br><br>Some background about the components needed for the described system</h1> |
- | <p> | + | <p style="text-align:left;"> |
| • Role of T4 Ligase in nature: to repair tRNA damage during the invasion of the bacteriophage (maybe cause of different anti codon usage in the phage) (“Thus, reprocessing could be yet another T4 device to adapt the translation apparatus to post-infection codon usage”) (Amitsur et al., 1987)(C. Kiong Ho, Li Kai Wang 2004)<br> | | • Role of T4 Ligase in nature: to repair tRNA damage during the invasion of the bacteriophage (maybe cause of different anti codon usage in the phage) (“Thus, reprocessing could be yet another T4 device to adapt the translation apparatus to post-infection codon usage”) (Amitsur et al., 1987)(C. Kiong Ho, Li Kai Wang 2004)<br> |
| • Problem: Ribosome will get stuck because of the double strand RNA<br> | | • Problem: Ribosome will get stuck because of the double strand RNA<br> |
Line 413: |
Line 413: |
| <img> | | <img> |
| </p> | | </p> |
| + | <p>For extended information follow the <a href="https://static.igem.org/mediawiki/2014/c/c5/Technion-Israel-RNA_Splint2.pdf" target="_blank">link</a></p> |
| </center> | | </center> |
| <hr> | | <hr> |
Line 477: |
Line 478: |
| <h1><br>Azobenzene aggregate Nano-Particles (NPs)</h1> | | <h1><br>Azobenzene aggregate Nano-Particles (NPs)</h1> |
| <p style="font-size:1.1em;">We established our iGEM azobenzene biological conceptions based on the Nano-word. We collaborated with Weizmann institute to test azobenzene molecules. We have seen that azobenzene can aggregate various NPs like iron oxide, gold and big particles like silica (see reference and TEM figures), and based on this behaviors we established our vision to use azobenzene as a photo-induced molecule to aggregate bacteria forming a synthetic biofilm.</p> | | <p style="font-size:1.1em;">We established our iGEM azobenzene biological conceptions based on the Nano-word. We collaborated with Weizmann institute to test azobenzene molecules. We have seen that azobenzene can aggregate various NPs like iron oxide, gold and big particles like silica (see reference and TEM figures), and based on this behaviors we established our vision to use azobenzene as a photo-induced molecule to aggregate bacteria forming a synthetic biofilm.</p> |
| + | |
| + | <p><br><p>For full azobenzene protocol follow the <a href="https://static.igem.org/mediawiki/2014/0/0e/Technion-Israel-Azobenzene.pdf" target="_blank">link</a></p> |
| + | <p><br><p>For extended information follow the <a href="https://static.igem.org/mediawiki/2014/f/fa/Technion-Israel-Simple_azo.pdf" target="_blank">link</a></p> |
| </center> | | </center> |
| <hr> | | <hr> |
Line 503: |
Line 507: |
| <h1 style="font-size:1.5em;">Introduction</h1> | | <h1 style="font-size:1.5em;">Introduction</h1> |
| <p style="font-size:1.1em; line-height:1.75em;"> | | <p style="font-size:1.1em; line-height:1.75em;"> |
- | Some substances that we want to detect cannot diffuse into the cell or they do not activate promoters. To test for these substances we want utilize the E.coli’s EnvZ/ompR two-component signaling system (Forst & Roberts, 1994) by creating chimera proteins that detect the desired substance.<br> | + | Some substances that we want to detect cannot diffuse into the cell or they do not activate promoters. To test for these substances we want utilize the modularity of E.coli’s EnvZ/ompR two-component signaling system by creating chimera proteins that detect the desired substance.<br> |
| <img src="https://static.igem.org/mediawiki/2014/7/71/Technion-Israel-hk.png"><br> | | <img src="https://static.igem.org/mediawiki/2014/7/71/Technion-Israel-hk.png"><br> |
| <b>Figure 1: How a chimaera protein would use the EnvZ/ompR two-component signalling system to trigger our system</b><br><br> | | <b>Figure 1: How a chimaera protein would use the EnvZ/ompR two-component signalling system to trigger our system</b><br><br> |
Line 510: |
Line 514: |
| <h1 style="font-size:1.5em;"><br>TaZ Construct</h1> | | <h1 style="font-size:1.5em;"><br>TaZ Construct</h1> |
| <p style="font-size:1.1em; line-height:1.75em;"><b>Completed and Biobricked</b></p> | | <p style="font-size:1.1em; line-height:1.75em;"><b>Completed and Biobricked</b></p> |
- | <p style="font-size:1.1em; line-height:1.75em;">We found the receptor, tar-envZ biobrick (Bba_C0082) which contains the coding sequence for Taz. In order to use the Taz we added the promoter Pcat (Bba_I14033), an RBS (Bba_B0034) and double terminator (Bba_B0015). Thus we created the Taz construct biobrick BBa_K1343016. Click on the link to continue reading about our TaZ experimentation.</p> | + | <p style="font-size:1.1em; line-height:1.75em;">We found the receptor, tar-envZ biobrick (Bba_C0082) which contains the coding sequence for Taz. In order to use the Taz we added the promoter Pcat (Bba_I14033), an RBS (Bba_B0034) and double terminator (Bba_B0015). Thus we created the Taz construct biobrick <a href="http://parts.igem.org/Part:BBa_K1343003" target="_blank">BBa_K1343016</a>. Click on the link to continue reading about our <a href="https://2014.igem.org/Team:Technion-Israel/Experiments#taz">TaZ experimentation</a>.</p> |
| <p>Two different E. coli strains were tested:<br> | | <p>Two different E. coli strains were tested:<br> |
| (1)BW25113 - parent strain for the Keio collection<br> | | (1)BW25113 - parent strain for the Keio collection<br> |
Line 516: |
Line 520: |
| (These strains were given to us by Lior Zelcbuch, Elad Hertz from Ron Milo’s lab at the Weizmann Institute of Science)<br><br> | | (These strains were given to us by Lior Zelcbuch, Elad Hertz from Ron Milo’s lab at the Weizmann Institute of Science)<br><br> |
| The goal was to compare the expression in the wild type and in the ΔEnvZ mutant. We expected that in the wild type the expression will be greater than in the mutant since the natural EnvZ/ompR system will cause expression of the RFP.</p> | | The goal was to compare the expression in the wild type and in the ΔEnvZ mutant. We expected that in the wild type the expression will be greater than in the mutant since the natural EnvZ/ompR system will cause expression of the RFP.</p> |
| + | |
| + | <p><br><p>For extended information follow the <a href="https://static.igem.org/mediawiki/2014/7/7d/Technion-Israel-Histidine_Kinase_-_long_for_wiki.pdf" target="_blank">link</a></p> |
| </center> | | </center> |
| <hr> | | <hr> |
Line 546: |
Line 552: |
| We tried several times, once we even went all the way to the Weizmann Institute in Rehovot where Lior Z., Elad and Sagit Yahav helped us. But to no avail! We just couldn’t manage to knock out the genes! <br> | | We tried several times, once we even went all the way to the Weizmann Institute in Rehovot where Lior Z., Elad and Sagit Yahav helped us. But to no avail! We just couldn’t manage to knock out the genes! <br> |
| </p> | | </p> |
| + | <p><br><p>For extended information follow the <a href="https://static.igem.org/mediawiki/2014/1/1e/Gene_Deletion_-_wiki.pdf" target="_blank">link</a></p> |
| <hr> | | <hr> |
| </center> | | </center> |
Line 560: |
Line 567: |
| | | |
| <div id="footer-wrapper" class="wrapper"> | | <div id="footer-wrapper" class="wrapper"> |
- | <div class="title" id="newmethod">New Method</div> | + | <div class="title" id="newmethod">New Standard</div> |
| <div id="footer" class="container"> | | <div id="footer" class="container"> |
| <header class="style1info"> | | <header class="style1info"> |
Line 912: |
Line 919: |
| </ul> | | </ul> |
| </div> | | </div> |
| + | |
| + | |
| + | </body> |
| + | |
| | | |
| </body> | | </body> |
| </html> | | </html> |